Safety and Efficacy of Anakinra Treatment for Patients With Post Acute Covid Syndrome
The PRECISION is a proof-of-concept, phase II randomized clinical trial aiming to evaluate the efficacy and safety of anakinra in patients with Post-Acute COVID Syndrome (PACS) of the pro-inflammatory respiratory phenotype. Improvement is measured by a composite endpoint, namely, the "Score of PACS progression reversal"
Age equal to or above 18 years [+7]
Age below 18 years [+15]